AI Plaque Scanning Cuts Heart Disease Guesswork With 40% Plaque Reduction Proof
Simon Hill's coronary plaque dropped 40% in 16 months. Cardiologist Dr. Campbell Rogers explains what that means and who should get scanned.
Summary
Host Simon Hill discovered soft coronary plaque on a CT scan in late 2024, then rescanned 16 months later to find a 40% reduction in plaque volume. In this episode of The Proof, he questions interventional cardiologist Dr. Campbell Rogers — Chief Medical Officer at Heartflow — about whether that result is clinically meaningful. They discuss the difference between calcium scoring, coronary CT angiography, and AI-assisted plaque analysis, explaining why a zero calcium score can still miss dangerous soft plaque. Rogers argues that visualizing actual plaque drives better patient adherence to statins and lifestyle changes than abstract biomarkers like ApoB alone. The conversation covers plaque rupture mechanics, low-attenuation plaque risk, and practical guidance on who should seek advanced cardiac imaging.
Detailed Summary
Heart disease kills more people than any other condition, yet for decades clinicians relied on indirect risk proxies — cholesterol panels, stress tests, calcium scores — rather than directly visualizing arterial plaque. AI-powered coronary CT angiography analysis now changes that calculus, and this podcast episode makes the case compellingly through a cardiologist's expertise and a host's personal data.
Simon Hill, who holds a master's in nutrition science, underwent a Heartflow AI plaque analysis in late 2024 after a CT scan revealed a small amount of soft plaque in his coronary arteries. Sixteen months later, a follow-up scan showed approximately 40% less plaque volume. Hill then sat down with Dr. Campbell Rogers — an interventional cardiologist, former Harvard faculty member who directed the catheterization laboratory at Brigham and Women's Hospital, and now Chief Medical Officer at Heartflow — to interrogate whether that result is real and what it means.
Rogers explains that calcified plaque, often flagged by calcium scores, is paradoxically a marker of stabilization, while soft non-calcified plaque — particularly low-attenuation plaque — is the high-rupture-risk lesion responsible for most acute coronary events. A calcium score of zero provides false reassurance because it cannot detect soft plaque, which is exactly the type Hill had. Heartflow's AI analyzes standard CT coronary angiogram images to quantify total plaque burden, composition, and hemodynamic significance within 90 minutes.
Hill's 40% reduction came after initiating statin therapy alongside continued aggressive lifestyle optimization. Rogers cites a JAMA study tracking plaque in prostate cancer patients as further validation that the platform detects real biological change. He argues that showing patients their actual plaque — rather than telling them their ApoB is elevated — dramatically improves medication adherence and motivates behavioral change.
The episode also addresses practical questions: how long to wait between scans, how Heartflow compares to competitors Cleerly and QAngio, and which patients should discuss coronary CT angiography with their physicians. Caveats include radiation exposure, cost and access barriers, and the reality that this remains a single individual's n-of-1 experience.
Key Findings
- A calcium score of zero does not rule out dangerous soft plaque; coronary CT angiography with AI analysis is required to detect it.
- Simon Hill's soft coronary plaque volume fell approximately 40% over 16 months following statin initiation and lifestyle changes.
- Low-attenuation non-calcified plaque carries the highest rupture risk and is invisible to standard calcium scoring.
- Visualizing actual plaque rather than quoting ApoB numbers measurably improves patient adherence to statins and lifestyle interventions.
- AI plaque analysis (Heartflow) quantifies plaque burden and hemodynamic significance from standard CT scans in about 90 minutes.
Methodology
This is a podcast episode, not a peer-reviewed study. The central data point is a single individual's (Simon Hill) serial Heartflow coronary CT angiography results taken approximately 16 months apart. Dr. Rogers references supporting published research including a JAMA study tracking plaque in prostate cancer patients, but primary methodology details are not independently verifiable from this source.
Study Limitations
This summary is based on a podcast episode, not a peer-reviewed publication, so claims cannot be independently verified through methodology review. The 40% plaque reduction is a single individual's n-of-1 result and cannot be generalized without controlled clinical data. Radiation exposure, cost, access disparities, and the need for repeat imaging are real trade-offs not fully quantified in this format.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: